-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atypical hemolytic uremia syndrome (aHUS) is a rare disease characterized by acute kidney injury, plate plate plate reduction, and microvascular pathogenic hemolytic anemia, with an event rate of about 0.5 per million.
aHUS affects adults and children, and patients in critical condition in hospital settings often need supportive treatment, including dialysis, in the Intensive Care Unit (ICU).
in many cases, aHUS patients may have poor prognosis, with 56 per cent of adults and 29 per cent of children receiving supportive treatment alone developing end-stage kidney disease or death within a year.
Ministry of Health, Labour and Human Rights (MHLW) has approved ULTOMIRIS® (ravulizumab) for adults and children with atypical hemolytic uremia syndrome (aHUS), pharmaceutical company Alexion Pharmaceuticals announced recently.
ULTOMIRIS is the first and only long-acting C5 inhibitor for aHUS.
Shoichi Maruyama, director of nephrology at Nagoya University Hospital in Japan, said: "The aim of aHUS therapy is to prevent the body from attacking its own immune system by inhibiting uncontrolled C5 supplement activation.
important is that ULTOMIRIS shows good tolerance."
.
